
Profitability, historical returns, and peer comparisons.
According to Biogen Inc.’s latest financial reports and current stock price. The company's current ROE is 1.86%. This represents a change of 301.66% compared to the average of 0.46% of the last 4 quarters.
The mean historical ROE of Biogen Inc. over the last ten years is 22.78%. The current 1.86% ROE has changed -91.82% with respect to the historical average. Over the past ten years (40 quarters), BIIB's ROE was at its highest in in the June 2020 quarter at 13.64%. The ROE was at its lowest in in the December 2017 quarter at -2.36%.
Average
22.78%
Median
21.44%
Minimum
7.08%
Maximum
44.13%
Discovering the peaks and valleys of Biogen Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 68.79%
Maximum Annual ROE = 44.13%
Minimum Annual Increase = -65.50%
Minimum Annual ROE = 7.08%
| Year | ROE | Change |
|---|---|---|
| 2025 | 7.08% | -27.45% |
| 2024 | 9.76% | 24.46% |
| 2023 | 7.85% | -65.50% |
| 2022 | 22.74% | 59.24% |
| 2021 | 14.28% | -61.80% |
| 2020 | 37.39% | -15.28% |
| 2019 | 44.13% | 29.88% |
| 2018 | 33.98% | 68.79% |
| 2017 | 20.13% | -34.00% |
| 2016 | 30.50% | -19.40% |
The current ROE of Biogen Inc. (BIIB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
8.23%
5-year avg
12.34%
10-year avg
22.78%
Biogen Inc.’s ROE is greater than Ionis Pharmaceuticals, Inc. (-110.84%), less than Vertex Pharmaceuticals Incorporated (20.08%), less than PTC Therapeutics, Inc. (57.10%), less than United Therapeutics Corporation (19.18%), less than Alnylam Pharmaceuticals, Inc. (159.72%), less than Regeneron Pharmaceuticals, Inc. (15.07%), less than Amgen Inc. (85.59%), less than Eli Lilly and Company (83.65%), less than Pfizer Inc. (4.60%), less than AstraZeneca PLC (22.31%),
| Company | ROE | Market cap |
|---|---|---|
| -110.84% | $6.67B | |
| 20.08% | $139.16B | |
| 57.10% | $5.76B | |
| 19.18% | $26.10B | |
| 159.72% | $21.57B | |
| 15.07% | $95.80B | |
| 85.59% | $258.68B | |
| 83.65% | $1.33T | |
| 4.60% | $175.49B | |
| 22.31% | $293.13B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biogen Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biogen Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Biogen Inc.'s ROE?
How is the ROE calculated for Biogen Inc. (BIIB)?
What is the highest ROE for Biogen Inc. (BIIB)?
What is the 3-year average ROE for Biogen Inc. (BIIB)?
What is the 5-year average ROE for Biogen Inc. (BIIB)?
How does the current ROE for Biogen Inc. (BIIB) compare to its historical average?